MENT

MENT binds to the androgen receptor with high affinity, estimated at roughly 10 times the potency of testosterone, driving robust activation of AR-dependent gene transcription pathways responsible for protein synthesis, nitrogen retention, and satellite cell proliferation in skeletal muscle. Its 7-alpha methyl group renders it resistant to 5-alpha reductase, meaning it is not converted to a reduced metabolite in androgen-sensitive tissues the way testosterone is converted to DHT or nandrolone is converted to DHN. MENT itself acts directly on androgen receptors throughout the body, including the brain, prostate, and sexual tissues, which is why it maintains libido and sexual function unlike nandrolone. MENT aromatizes via the aromatase enzyme, but the product is 7-alpha-methyl-estradiol rather than estradiol. This methylated estrogen retains estrogenic activity and binds to estrogen receptors, but conventional aromatase inhibitors (anastrozole, letrozole) have diminished ability to block its formation. The mechanism behind this reduced AI efficacy appears related to the 7-alpha methyl group altering the substrate's interaction with the aromatase active site. MENT powerfully suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing LH and FSH to near-undetectable levels at relatively low doses. This profound gonadotropin suppression is the basis for its investigation as a male contraceptive, as it can reduce sperm production to azoospermia or severe oligospermia in most men. Despite its 19-nor classification, MENT does not appear to have the significant progestogenic activity that nandrolone exhibits, though some degree of progesterone receptor interaction has been reported in preclinical studies.